Air Pollution And Climate Change Fueling Growth In The Allergic Rhinitis Market: The Driving Engine Behind Allergic Rhinitis Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Allergic Rhinitis Market Size Growth Forecast: What to Expect by 2025?
In the past few years, a consistent growth has been observed in the allergic rhinitis market size. The market which is projected to surge from $15.22 billion in 2024 to $15.74 billion in 2025, suggests a compound annual growth rate (CAGR) of 3.4%. Factors such as exposure to allergens, environmental modifications, public awareness, escalating pollution, research and advancements on allergic rhinitis, along with an increase in disposable income have contributed to the historic period growth.

How Will the Allergic Rhinitis Market Size Evolve and Grow by 2029?
The market size for allergic rhinitis is projected to undergo consistent expansion in the forthcoming years. The anticipated growth will propel it to $18.49 billion by 2029, resulting in a Compound Annual Growth Rate (CAGR) of 4.1%. The predicted growth can be credited to an increased need for preventive measures, a rising elderly populace, urbanization, and health care expenditures. Upcoming trends for this period involve biologics and monoclonal antibodies, allergen detection technology, pediatric allergic rhinitis, allergen avoidance approaches, and digital health solutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

What Drivers Are Propelling the Growth of Allergic Rhinitis Market Forward?
The rise in air pollution and climate change are anticipated to drive the progress of the allergic rhinitis market. Air pollution, which involves harmful substances in the Earth's atmosphere, can negatively impact human health, environmental conditions, and the quality of our breathable air. Climate change is a term referring to long-term changes in weather patterns, such as changes in temperature, precipitation, and other weather-related factors. The role of air pollution as a significant environmental condition that contributes to the incidence and worsening of allergic rhinitis is increasingly being understood, revealing the complex link between air quality and respiratory health. For example, the United States Environmental Protection Agency, a US government agency, reported in August 2024 that around 66 million tons of pollutants were discharged into the atmospheric environment throughout the United States in 2023. Hence, high air pollution levels and climate change continue to directly impact the allergic rhinitis market. The expanding use of corticosteroid treatment for allergic rhinitis is predicted to boost the allergic rhinitis market forward. This treatment approach, often referred to as steroid treatment, utilizes medications known as corticosteroids or simply steroids. They are frequently employed in treating allergic rhinitis as they aid in decreasing inflammation in the nasal passages and help mitigate the symptoms of the disease. For example, in September 2023, the American Society for Clinical Pharmacology and Therapeutics, a professional organization based in the United States, recorded an average usage of oral corticosteroids of 6.8% in the U.S., 17.5% in Taiwan, and 2.2% in Denmark, with annual increases ranging from 0.1% to 0.17%. These prescriptions were predominantly short-lived (1-29 days) and were prescribed for otherwise healthy adults suffering from self-limited conditions like respiratory infections. Consequently, the rise in corticosteroid treatments for allergic rhinitis stimulates the growth of the allergic rhinitis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12926&type=smp

Which Emerging Trends Are Transforming the Allergic Rhinitis Market in 2025?
Top corporations in the allergic rhinitis market are focusing on the creation of innovative drugs to maintain their market dominance. For instance, in August 2022, UK's Hikma Pharmaceuticals PLC and Switzerland's Glenmark Specialty S.A. received approval from the United States Food and Drug Administration (FDA) for their product Ryaltris. This is the first combined-dose drug made available in a handy nasal spray that addresses both nasal and eye symptoms of seasonal allergic rhinitis in adults and children aged 12 and above. Remarkably, the relief from nasal symptoms begins within 15 minutes of administering the first dose.

What Are the Key Segments in the Allergic Rhinitis Market?
The allergic rhinitis market covered in this report is segmented -

1) By Type: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis
2) By Treatment: Antihistamines, Corticosteroids, Immunotherapy, Decongestants, Other Treatments
3) By Test: Skin Test, IgE Radioallergosorbent (RAST) Test, Complete Blood Count
4) By Route Of Administration: Oral, Nasal, Other Route Of Administration
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Stores

Subsegments:
1) By Seasonal Allergic Rhinitis: Pollen Allergy, Mold Allergy
2) By Perennial Allergic Rhinitis: Dust Mite Allergy, Pet Allergy, Mold Allergy
3) By Occupational Allergic Rhinitis: Chemical Allergens, Biological Allergens

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12926&type=smp

Who Are the Key Players Shaping the Allergic Rhinitis Market's Competitive Landscape?
Major companies operating in the allergic rhinitis market are Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Limited, Menarini Group, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Limited, Endo Pharmaceuticals Inc., Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharma Ltd., Almirall S.A., Kyowa Kirin Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Akorn Inc.

What Geographic Markets Are Powering Growth in the Allergic Rhinitis Market?
North America was the largest region in the allergic rhinitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in allergic rhinitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12926

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.